Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
5,490 people get AMGN articles and Market Currents by email alert.
Get email alerts on AMGN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (Thu, 4:18PM)
-
-
PR Newswire (Wed, 6:00PM)
-
-
-
-
-
-
-
PR Newswire (May 9, 2013)
-
-
-
After AbbVie's Humira: What Next?Peter Geschek • Mon, May 6 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Why Amgen Still Has Valuation Upside RemainingValuentum • Fri, Feb 15 -
-
Is Amgen Running Out Of Steam In 2013?StockRiters • Tue, Jan 22 -
-
-
-
-
-
-
Amgen Management Discusses Q3 2012 Results - Earnings Call TranscriptTue, Oct 23, 2012
-
Amgen Management Discusses Q2 2012 Results - Earnings Call TranscriptThu, Jul 26, 2012
-
Amgen's CEO Discusses Q1 2012 Results - Earnings Call TranscriptTue, Apr 24, 2012
-
Amgen's CEO Discusses Q4 2011 Results - Earnings Call TranscriptThu, Jan 26, 2012
-
Amgen's CEO Discusses Q3 2011 Results - Earnings Call TranscriptMon, Oct 24, 2011
-
Amgen's CEO Discusses Q2 2011 Results - Earnings Call TranscriptFri, Jul 29, 2011
-
Amgen's CEO Discusses Q1 2011 Results - Earnings Call TranscriptWed, Apr 20, 2011
-
Amgen's CEO Discusses Q4 2010 Results - Earnings Call TranscriptTue, Jan 25, 2011
-
Amgen Management Discusses Q3 2010 Results - Earnings Call TranscriptTue, Oct 26, 2010
-
Amgen Q2 2010 Earnings Call TranscriptFri, Jul 30, 2010
-
Amgen Inc. Q1 2010 Earnings Call TranscriptThu, Apr 22, 2010
-
Amgen, Inc. Q4 2009 Earnings Call TranscriptMon, Jan 25, 2010
-
Amgen, Inc. Q3 2009 Earnings Call TranscriptWed, Oct 21, 2009
-
Amgen, Inc. Q2 2009 Earnings Call TranscriptTue, Jul 28, 2009
-
Amgen Inc., F1Q09Earnings Call TranscriptThu, Apr 23, 2009
-
Amgen Inc. Q4 2008 Earnings Call TranscriptTue, Jan 27, 2009
-
PR Newswire (Thu, 4:18PM)
-
PR Newswire (Wed, 6:00PM)
-
PR Newswire (May 9, 2013)
-
at CNBC.com (May 1, 2013)
-
at CNBC.com (Apr 26, 2013)
-
at MarketWatch.com (Apr 26, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at MarketWatch.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at MarketWatch.com (Apr 23, 2013)
-
at MarketWatch.com (Apr 21, 2013)
AMGN vs. ETF Alternatives
Company Description
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” and “us”) is the world’s largest independent biotechnology medicines company. We discover, develop, manufacture and market medicines for grievous illnesses. We focus solely on human therapeutics and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, December 13, 2012, 5:37 PM Amgen's (AMGN) board has approved a $2B increase to its share buyback program. This amount is in addition to approximately $500M remaining under its existing $10B share repurchase program. Amgen expects that the increase being announced today will cover share repurchases into 2014. Comment! [Healthcare]
- Thursday, December 13, 2012, 5:22 PM Amgen (AMGN) declares $0.47/share quarterly dividend, 31% increase from prior dividend of $0.36. Forward yield 2.11%. For shareholders of record Feb. 13. Payable Mar. 07. Ex-div date Feb. 11. The board approved an increase in share repurchase program of $2.0B. (PR) Comment! [Dividends]
- Monday, December 10, 2012, 8:37 AM Amgen (AMGN) agrees to acquire deCODE Genetics, which analyzes the links between the genome and susceptibility to disease, in a deal that values the Icelandic company at $415M. deCODE Genetics has discovered genetic risks for dozens of illnesses, including cardiovascular problems and cancer. With the transaction not requiring regulatory approval, Amgen expects it to close by the end of the month. (PR) Comment! [Healthcare, M&A]
- Wednesday, November 21, 2012, 10:09 AM SA author Austrolib provides a run-through of cancer vaccines from the "underwhelming to the exciting." The latter includes OncoVEX from Amgen (AMGN), which would be a buy if it weren't "skirting its all-time highs of $89 a share." Even more interesting are DCVax-L (brain) and DCVax-Direct (inoperable tumors) from Northwest Biotherapeutics (NWBO.OB). The problem is that Northwest has little cash and lots of debt notes. Comment! [Healthcare, Quick Ideas]
- Tuesday, November 6, 2012, 3:45 AM A year after Lipitor lost its patent protection, a number companies are making headway on the next generation of medicines for reducing LDL, or "bad cholesterol." Much interest focuses on the cholesterol-regulating gene PCSK9 in the liver, with Amgen (AMGN) (see [[here]]) and Pfizer (PFE) yesterday presenting data showing that their drugs performed well in mid-stage trials. Sanofi (SNY) and partner Regeneron (REGN) announced a massive Phase III trial for their treatment. Comment! [Healthcare]
- Monday, November 5, 2012, 3:57 PM Amgen (AMGN) says Phase 2 studies of its investigational antibody AMG 145, in combination with statin therapy, resulted in a 56% reduction in low density lipoprotein cholesterol, the "bad" cholesterol, in patients with heterozygous familial hypercholesterolemia. The study was published in Circulation and presented at the American Heart Association Scientific Sessions 2012. Comment! [Healthcare]
- Wednesday, October 24, 2012, 11:15 AM Amgen (AMGN +1.3%) ticks up after its Q3 beat on bottom line estimates late yesterday. Net earnings more than doubled as newer products boosted revenue growth and its bottom line was aided by an absence of litigation-related charges. The company also guided FY12 revenue higher, now expecting to earn around $17.2B - $17.3B and its EPS to $6.50 - $6.60. The Street view was for $17.06 bln and and EPS number of $6.33. 1 Comment [Healthcare, Earnings, On the Move]
- Tuesday, October 23, 2012, 4:12 PM Amgen (AMGN): Q3 EPS of $1.67 beats by $0.20. Revenue of $4.3B (+10% Y/Y) in-line. Shares +0.3% AH. (PR) Comment! [Earnings, Healthcare]
- Tuesday, October 23, 2012, 12:10 AM Notable earnings after Tuesday’s close: ACE, AFL, ALTR, AMGN, BCR, BNNY, BRCM, BWLD, CBI, CHRW, FB, FBC, FBHS, FTI, GILD, HTS, ILMN, INVN, IRBT, JNPR, NBR, NFLX, NFX, NSC, PLCM, PNRA, QCOR, RFMD, STM, TPX, TSS, UIS, VMW, WYNN Comment! [Earnings]
- Monday, October 22, 2012, 5:35 PM Notable earnings after Tuesday’s close: ACE, AFL, ALTR, AMGN, BCR, BNNY, BRCM, BWLD, CBI, CHRW, FB, FBC, FBHS, FTI, GILD, HTS, ILMN, INVN, IRBT, JNPR, NBR, NFLX, NFX, NSC, PLCM, PNRA, QCOR, RFMD, STM, TPX, TSS, UIS, VMW, WYNN Comment! [Earnings]
- Monday, October 22, 2012, 10:37 AM Amgen (AMGN +1.3%) ticks up this morning following an upgrade to Buy on valuation at Deutsche Bank ahead of its earnings report tomorrow. The firm says that despite the stock's strong move this year - from $67 in early June to its current $88 handle - it still trades at a discount to its peers and has a solid pipeline to spur continued growth. Deutsche also expects the dividend to continue to improve, and anticipates a dividend yield of 3% by 2014. Comment! [Healthcare, On the Move]
- Thursday, October 11, 2012, 9:11 AM Amgen (AMGN) declares $0.36/share quarterly dividend, in line with previous. Forward yield 1.70%. For shareholders of record Nov 15. Payable Dec 07. Ex-div date Nov 13. (PR) 1 Comment [Dividends]
- Thursday, September 20, 2012, 7:26 PM Amgen (AMGN) says the FDA has approved a new indication for Prolia as a treatment to increase bone mass in men with osteoporosis at high risk for fracture. Prolia is the first FDA-approved subcutaneous injection administered every six months. Studies of men with low bone mineral density who took the treatment resulted in significantly greater bone density gains when compared to a placebo. Comment! [Healthcare]
- Wednesday, September 12, 2012, 10:56 AM Some comments from Amgen's (AMGN) CFO Jon Peacock out of the Morgan Stanley Healthcare Conference: Pipeline becoming more visible, reiterates FY12 EPS and revenue growth forecasts; biggest growth opportunities are outside the U.S., so consequently, the company will be looking to step up its international business; plans "meaningful" increases to its dividend over time, with more moderated buybacks through 2015. (Webcast). Comment! [Healthcare]
- Monday, August 13, 2012, 4:46 PM More on Array BioPharma (ARRY): FQ4 beats on a 9% Y/Y jump in total revenue. Net losses were pared significantly from the prior year period, as its top line was boosted by a jump in sales and its bottom line benefited from milestone payments from AMGN. Shares +6.6% AH. Comment! [Healthcare, Earnings, On the Move]
- Wednesday, August 8, 2012, 4:09 PM Amgen (AMGN) says that based upon the recommendation of an independent Data Monitoring Committee, it's terminating its Phase 3 study of its pancreatic cancer drug Ganitumab. After reviewing the pre-planned interim analysis, the committee concluded that the drug was unlikely to demonstrate a statistically significant improvement towards the primary endpoint of overall survival. Shares -0.9% AH. Comment! [Healthcare]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
paulalmony
$AMGN run-up today is way overdone. Epogene is coming off patent soon. While Affymax may not prove to be a worthy competitor, Roche will. - View all 0 replies
-
Tony Kau
$AMGN time to take profits - looking exhausted here http://ow.ly/i/1A3MR http://ow.ly/i1PHS - View all 0 replies
-
Dividend Sheet
$INN $DRE and $ED are the best yielding stocks going ex-dividend on Monday + http://stks.co/s26h + I like $SCCO $AMGN and $VLO - View all 0 replies
-
- View all 0 replies
-
Closet Iguana
Healthcare Cloud Computing Market is Expected to Reach USD 6.7B http://adf.ly/HsEQB $SNY $EMR $AMGN $GILD - View all 0 replies
-
The Scientist
$CYTK stock price makes absolutely NO sense. Omecamtiv and Tirasemtiv both potential revolutionary/blockbuster drugs. $AMGN partnered. - View all 0 replies
-
Jim Van Meerten
$AMGN - 100% Barchart technical buy signal - 3 new highs and up 1.34% in the last month - Relative Strength Index 63.30% - View all 0 replies
LATEST REPLIES